Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma

Thrombosis Research

Volumn 125, Issue , 2010, Pages S96-S102

  Wun, Ted ^a,b,c   White, Richard H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Veterans Administration   (United States)

^c Davis Clinic PC   (United States)

Author keywords

Leukemia; Lymphoma; Myeloma; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT;

HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; PATHOLOGY; REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; VENOUS THROMBOEMBOLISM;

EID: 77955479993     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70024-4     Document Type: Article

References (60)

1. Falanga, A, Rickles, FR, Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:2 (1999), 173–182.
2. Khorana, AA, Francis, CW, Culakova, E, Kuderer, NM, Lyman, GH, Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110:10 (2007 Nov 15), 2339–2346.
3. Khorana, AA, Kuderer, NM, Culakova, E, Lyman, GH, Francis, CW, Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:10 (2008 May 15), 4902–4907.
4. Lee, AY, Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon 51:2–3 (2005 Feb-Mar), 150–157.
5. Chew, HK, Wun, T, Harvey, D, Zhou, H, White, RH, Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:4 (2006), 458–464.
6. Levitan, N, Dowlati, A, Remick, SC, Tahsildar, HI, Sivinski, LD, Beyth, R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78:5 (1999), 285–291.
7. Rodriguez, AO, Wun, T, Chew, H, Zhou, H, Harvey, D, White, RH, Venous thromboembolism in ovarian cancer. Gynecol Oncol 105:3 (2007), 784–790.
8. Semrad, TJ, O'Donnell, R, Wun, T, Chew, H, Harvey, D, Zhou, H, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106:4 (2007), 601–608.
9. Blom, JW, Doggen, CJ, Osanto, S, Rosendaal, FR, Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:6 (2005), 715–722.
10. Falanga, A, Marchetti, M, Venous thromboembolism in the hematologic malignancies. J Clin Oncol 27:29 (2009 Oct 10), 4848–4857.
11. Eby, C, Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 145:2 (2009 Apr), 151–163.
12. Ku, GH, White, RH, Chew, HK, Harvey, DJ, Zhou, H, Wun, T, Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 113:17 (2009 Apr 23), 3911–3917.
13. Escudier, SM, Kantarjian, HM, Estey, EH, Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 20:5–6 (1996), 435–439.
14. Alcalay, A, Wun, T, Khatri, V, Chew, HK, Harvey, D, Zhou, H, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 24:7 (2006), 1112–1118.
15. Barbui, T, Falanga, A, Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 27:6 (2001), 593–604.
16. Ziegler, S, Sperr, WR, Knobl, P, Lehr, S, Weltermann, A, Jager, U, et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 115:1–2 (2005), 59–64.
17. De Stefano, V, Sora, F, Rossi, E, Chiusolo, P, Laurenti, L, Fianchi, L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 3:9 (2005 Sep), 1985–1992.
18. Khorana, AA, Francis, CW, Culakova, E, Fisher, RI, Kuderer, NM, Lyman, GH, Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:3 (2006 Jan 20), 484–490.
19. Athale, UH, Chan, AK, Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thromb Res 111:6 (2003), 321–327.
20. Athale, UH, Chan, AK, Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 111:4–5 (2003), 199–212.
21. Athale, UH, Chan, AK, Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 111:3 (2003), 125–131.
22. Caruso, V, Iacoviello, L, Di Castelnuovo, A, Storti, S, Mariani, G, de Gaetano, G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 108:7 (2006), 2216–2222.
23. Mohren, M, Markmann, I, Jentsch-Ullrich, K, Koenigsmann, M, Lutze, G, Franke, A, Increased risk of venous thromboembolism in patients with acute leukemia. Br J Cancer 94:2 (2006), 200–202.
24. Melillo, L, Grandone, E, Colaizzo, D, Cappucci, F, Valvano, MR, Cascavilla, N, Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 117:4 (2007), 215–220.
25. Sorensen, HT, Mellemkjaer, L, Olsen, JH, Baron, JA, Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:25 (2000), 1846–1850.
26. Ruf, W, Mueller, BM, Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32:Suppl 1 (2006), 61–68.
27. Winter, PC, The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol 24:3 (2006), 126–133.
28. Komrokji, RS, Uppal, NP, Khorana, AA, Lyman, GH, Kaplan, KL, Fisher, RI, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 47:6 (2006 Jun), 1029–1033.
29. Ottinger, H, Belka, C, Kozole, G, Engelhard, M, Meusers, P, Paar, D, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 54:3 (1995 Mar), 186–194.
30. Khorana, AA, Francis, CW, Culakova, E, Lyman, GH, Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104:12 (2005 Dec 15), 2822–2829.
31. Goldschmidt, N, Linetsky, E, Shalom, E, Varon, D, Siegal, T, High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 98:6 (2003 Sep 15), 1239–1242.
32. Athale, UH, Nagel, K, Khan, AA, Chan, AK, Thromboembolism in children with lymphoma. Thromb Res 122:4 (2008), 459–465.
33. Conlon, SJ, White, RH, Chew, HK, Wun, T, Incidence of Venous Thromboembolism in Patients wtih Lymphoma. J Thromb Haemost, 7(s2), 2009, 168.
34. Wada, H, Sase, T, Yamaguchi, M, Hypercoagulant states in malignant lymphoma. Exp Oncol 27:3 (2005 Sep), 179–185.
35. Kumar, SK, Rajkumar, SV, Dispenzieri, A, Lacy, MQ, Hayman, SR, Buadi, FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:5 (2008 Mar 1), 2516–2520.
36. Kyle, RA, Rajkumar, SV, Multiple myeloma. Blood 111:6 (2008 Mar 15), 2962–2972.
37. Kristinsson, SY, Fears, TR, Gridley, G, Turesson, I, Mellqvist, UH, Bjorkholm, M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112:9 (2008 Nov 1), 3582–3586.
38. Sallah, S, Husain, A, Wan, J, Vos, P, Nguyen, NP, The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 15:10 (2004 Oct), 1490–1494.
39. Srkalovic, G, Cameron, MG, Rybicki, L, Deitcher, SR, Kattke-Marchant, K, Hussein, MA, Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101:3 (2004 Aug 1), 558–566.
40. Baz, R, Li, L, Kottke-Marchant, K, Srkalovic, G, McGowan, B, Yiannaki, E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80:12 (2005 Dec), 1568–1574.
41. El Accaoui, RN, Shamseddeen, WA, Taher, AT, Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 97:6 (2007 Jun), 1031–1036.
42. Khorana, AA, Streiff, MB, Farge, D, Mandala, M, Debourdeau, P, Cajfinger, F, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 27:29 (2009 Oct 10), 4919–4926.
43. Rajkumar, SV, Jacobus, S, Callander, NS, Fonseca, R, Vesole, DH, Williams, ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol, 2009 Oct 21.
44. Palumbo, A, Rajkumar, SV, Dimopoulos, MA, Richardson, PG, San Miguel, J, Barlogie, B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:2 (2008 Feb), 414–423.
45. Richardson, PG, Mitsiades, C, Schlossman, R, Ghobrial, I, Hideshima, T, Munshi, N, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 8:7 (2008 Jul), 1053–1072.
46. Lacy, MQ, Hayman, SR, Gertz, MA, Dispenzieri, A, Buadi, F, Kumar, S, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27:30 (2009 Oct 20), 5008–5014.
47. Anagnostopoulos, A, Weber, D, Rankin, K, Delasalle, K, Alexanian, R, Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:5 (2003 Jun), 768–771.
48. Weber, D, Rankin, K, Gavino, M, Delasalle, K, Alexanian, R, Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:1 (2003 Jan 1), 16–19.
49. Kumar, S, Gertz, MA, Dispenzieri, A, Lacy, MQ, Geyer, SM, Iturria, NL, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78:1 (2003 Jan), 34–39.
50. Rajkumar, SV, Blood, E, Vesole, D, Fonseca, R, Greipp, PR, Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:3 (2006 Jan 20), 431–436.
51. Palumbo, A, Bringhen, S, Caravita, T, Merla, E, Capparella, V, Callea, V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:9513 (2006 Mar 11), 825–831.
52. Offidani, M, Corvatta, L, Marconi, M, Olivieri, A, Catarini, M, Mele, A, et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 5:4 (2004), 312–317.
53. Schutt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Hoiczyk, M, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 74:1 (2005 Jan), 40–46.
54. Richardson, PG, Schlossman, RL, Weller, E, Hideshima, T, Mitsiades, C, Davies, F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:9 (2002 Nov 1), 3063–3067.
55. Weber, DM, Chen, C, Niesvizky, R, Wang, M, Belch, A, Stadtmauer, EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:21 (2007 Nov 22), 2133–2142.
56. Zangari, M, Elice, F, Fink, L, Tricot, G, Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 33:4 (2007 Jun), 339–349.
57. Zangari, M, Saghafifar, F, Anaissie, E, Badros, A, Desikan, R, Fassas, A, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13:3 (2002 Apr), 187–192.
58. Elice, F, Fink, L, Tricot, G, Barlogie, B, Zangari, M, Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134:4 (2006 Aug), 399–405.
59. Elhasid, R, Lanir, N, Sharon, R, Weyl, BA, Levin, C, Postovsky, S, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 12:5 (2001), 367–370.
60. Imberti, D, Vallisa, D, Anselmi, E, Moroni, CF, Berte, R, Lazzaro, A, et al. Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia. Tumori 90:4 (2004), 390–393.